Minimal Residual Disease Assessment (MRD): New study explores whether a blood test can detect cancer recurrence earlier than traditional methods
Brussels, Belgium, 4 August 2025. The European Organisation for Research and Treatment of Cancer (EORTC) and Guardant Health are proud to announce the enrolment of the first patient in the Head & Neck cohort of the 2148 MRD, a downstream project of the SPECTA platform.
This international study is investigating whether a simple blood test can detect early signs of cancer returning after treatment. By identifying recurrence before it becomes visible on scans or causes symptoms, the study aims to support earlier clinical decisions and improve long-term outcomes for patients.
The 2148 MRD study focuses on patients with solid tumours who are disease-free after curative treatment but remain at high risk of relapse. It uses circulating tumour DNA (ctDNA) analysis to monitor for minimal residual disease, small traces of cancer that may persist in the body. The study will evaluate whether ctDNA can serve as a reliable early indicator of recurrence.
The first patient has been enrolled in the HPV-negative head and neck squamous cell carcinoma (HNSCC) cohort. This group includes patients with cancers of the oral cavity, larynx, hypopharynx, and oropharynx. These cancers are often aggressive and have a higher likelihood of returning, making them a key focus for MRD research.
The study aims to generate evidence that could help integrate ctDNA testing into routine cancer follow-up care.
“This study represents a critical step forward in understanding both the prognostic and predictive value of circulating tumour DNA (ctDNA) dynamics in locally advanced head and neck squamous cell carcinoma. By evaluating ctDNA, we aim to uncover valuable biomarkers that may aid in risk-stratification and treatment selection, as well as in guiding future treatment strategies, including therapeutic escalation or de-escalation. Participating in this research offers investigators the opportunity to contribute to a potentially practice-changing approach that could personalise care and improve outcomes for patients with head and neck cancer,” say Jean-Pascal Machiels and Marc Olivia, Study coordinators.
The 2148 MRD study reflects a growing commitment to advancing personalised cancer care by integrating innovative tools like ctDNA monitoring into clinical research. The insights gained may help shape future strategies for earlier intervention and more tailored follow-up in solid tumour management.
